Ion

Chopin Launches Advanced Streaming Service to Meet Consumer Demand and Increase Subscriber Base

Retrieved on: 
Saturday, May 27, 2023
Cheseaux-sur-Lausanne, Partnership, Internet service provider, Ion, OTT, Kudelski Group, BYOD, Frédéric Chopin, Video game, Mobile phone

In addition, Chopin will also wholesale the service to other mid-sized operators across Poland.

Key Points: 
  • In addition, Chopin will also wholesale the service to other mid-sized operators across Poland.
  • “We sought a partner that could help us successfully expand our broadcast proposition to also offer an OTT solution that aggregates the breadth of content our consumers demand,” said Bogdan Laga ,CEO at Chopin.
  • Reselling this service means Chopin will enable other similar-sized regional operators outside its footprint with a leading turn-key service.
  • Powered by NAGRA OpenTV Video Platform, the cloud-based solution utilizes the Ion user experience across a wide variety of streaming devices.

MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting

Retrieved on: 
Tuesday, May 16, 2023
Inflammation, Temperature, GH, Cryogenic electron microscopy, Endocrine gland, Risk, Cell, ALS, Virus, Gene, DSM-IV codes, Research, Gene expression, Ion, AUC, American Society of Gene and Cell Therapy, Liver, Neoplasm, AAV2, Kinetics, Death, Poster, HPLC, Genome, Safety, Neuron, Growth hormone, Muscular dystrophy, STR, Transfection, AAV, Hepatocyte, CAR, Sequence, Animal, CMV, Immune system, Cancer, AEX, Plasmid, PH, Neurological disorder, Human, NF-κB, Riboswitch, LDH, DSW, RNA, Skeletal muscle, CAG, Sure, Annual general meeting, Mouse, Society, FTD, Vaccine, Publication

RiboCAR is a synthetic riboswitch-based gene regulation system for precise regulation of CAR expression levels in CAR-T cell therapy via orally available small molecule.

Key Points: 
  • RiboCAR is a synthetic riboswitch-based gene regulation system for precise regulation of CAR expression levels in CAR-T cell therapy via orally available small molecule.
  • We demonstrate that with a bioavailable small molecule inducer, CAR-T activity can be precisely tuned and “remotely” controlled in vivo.
  • However, excessive amounts of transgene from unregulated vectors may limit the breadth of applicability of gene therapy.
  • Collectively, these results show we have established a robust platform to screen engineered promoters for applications to skeletal muscle gene therapies.

Advent Technologies Reports Q1 2023 Results

Retrieved on: 
Monday, May 15, 2023
Other Defense, Other Energy, Hardware, Sustainability, Alternative Energy, Energy, Technology, Defense, Environment, Green Technology, Engineering, Telecommunications, Manufacturing, Honey, The Cults of the Greek States, U.S. Department of Energy, Office of Inspector General, Partnership, Joint, JDA, U.S. Department of Defense Strategy for Operating in Cyberspace, HT, Methanol, ADN, Hyundai Motor Company, MEA, Research, Government, Impurity, Green, General assembly, Electrode, Hyundai, European, Hellenic State (1941–1944), Biofuel, Water, Catalysis, Advent, BASF, Quality control, R, Aircraft, Hipo, Siemens Energy, Cryptocurrency, Mobile phone, Renewable energy, Fine chemical, EU, Ion, Serene

Advent Technologies Holdings, Inc. (NASDAQ: ADN) (“Advent” or the “Company”), an innovation-driven leader in the fuel cell and hydrogen technology space, today announced consolidated financial results for the three months ended March 31, 2023.

Key Points: 
  • Advent Technologies Holdings, Inc. (NASDAQ: ADN) (“Advent” or the “Company”), an innovation-driven leader in the fuel cell and hydrogen technology space, today announced consolidated financial results for the three months ended March 31, 2023.
  • The focus towards the mobility sector and stationary power sector has been endorsed by significant opportunity wins for Advent,” said Dr. Vasilis Gregoriou, Chairman and CEO of Advent Technologies.
  • Hood Park R&D and Manufacturing Facility: On March 6, 2023, Advent announced that it opened its new R&D and manufacturing facility at Hood Park in Boston, Massachusetts.
  • Advent intends that its proprietary fuel cell products, such as Serene and Honey Badger 50™, will use the Ion Pair™ Advent MEAs beginning in 2024.

Adela Announces Appointment of Alan Williams as Chief Operating Officer

Retrieved on: 
Thursday, May 11, 2023
Ion semiconductor sequencing, Information technology, Ion, NGS, Cancer, SomaLogic, Thermo Fisher Scientific, Doctor of Philosophy, MRD, Organization, Data science, Management, Affymetrix

FOSTER CITY, Calif., May 11, 2023 /PRNewswire/ -- Adela, Inc., an innovator in minimal residual disease (MRD) detection and monitoring and early cancer detection with a routine blood test, announced today that Alan Williams, PhD has joined the company as Chief Operating Officer. Alan brings proven and deep expertise in product development, and in scaling clinical laboratory operations from his senior executive roles at Somalogic, Thermo Fisher Scientific (Ion Torrent), and Affymetrix.

Key Points: 
  • "I am thrilled to have joined the exceptionally innovative and talented team at Adela," said Alan Williams, Chief Operating Officer at Adela.
  • Adela has the opportunity to improve the care for the millions of people impacted by cancer."
  • "I am delighted to welcome Alan to Adela.
  • "Alan's leadership will help Adela accelerate bringing our products to market, leveraging the unique advantages of Adela's genome-wide methylation platform."

Salipro Biotech and DyNAbind Announce Milestone Achievement in Collaboration to Enable DEL for Membrane Proteins

Retrieved on: 
Tuesday, May 9, 2023
Membrane, Eurosport 1, G protein-coupled receptor, Ion, Dynamic linker, Membrane protein, SLC, Dynamics, Drug discovery, Surface plasmon resonance, Fine chemical

The collaboration combines the benefits of Salipro Biotech’s proprietary platform technology for membrane proteins with DyNAbind’s proprietary DNA-Encoded Library (DEL) technology to accelerate the development of novel drugs for challenging targets.

Key Points: 
  • The collaboration combines the benefits of Salipro Biotech’s proprietary platform technology for membrane proteins with DyNAbind’s proprietary DNA-Encoded Library (DEL) technology to accelerate the development of novel drugs for challenging targets.
  • Jens Frauenfeld, CEO of Salipro Biotech, said, "We are excited about this milestone in our collaboration with DyNAbind.
  • Our Salipro® platform technology for membrane proteins combined with DyNAbind's Dynamic Library technology has opened up new avenues for drug discovery against challenging targets.
  • This collaboration represents a significant development in the field of DEL and membrane proteins, showcasing the potential for cutting-edge technologies to transform drug discovery.

Global and Regional Surgical Robotics Market Analysis and Forecasts, 2022-2023 & 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 28, 2023
Technology, Robotics, Health, Surgery, Partnership, RA, Bed, MHLW, Ion, COVID-19, Cancer, Ministry of Health, Labour and Welfare, Curie Institute (Paris), Trial of the century, Ministry, Hospital, Patient, Johnson & Johnson, Microsurgery, Artificial intelligence, DePuy Synthes, Growth, Region, FDA, Ministry of Health, Intuitive Surgical, CMR Surgical, Safety, Country, Medical device, Pharmaceutical industry

The "Surgical Robotics Market - A Global and Regional Analysis: Focus on Type, Application, End-user, and Country - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Surgical Robotics Market - A Global and Regional Analysis: Focus on Type, Application, End-user, and Country - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • The increasing demand for minimally invasive surgeries, increasing demand for robotic-assisted surgeries, and increasing synergetic activities within the surgical robotics industry are some of the major opportunities in the global surgical robotics market.
  • The COVID-19 pandemic has impacted practically all sectors and social functions worldwide, including the global surgical robotics market.
  • The global surgical robotics market based on the end-user segment is dominated by the hospitals segment.

Avalanche Energy Achieves Record 200kv Electrostatic Fusion Milestone and Closes $40 Million Series A Funding Round

Retrieved on: 
Monday, April 24, 2023
Nuclear fusion, Defense Innovation Unit, University, Autodesk, Spacecraft, Ion, Noetics, Clear Path Alternative School, Avalanche, Founders Fund, Green Climate Fund, Jan Vansina, Seed, Transport, Lithium

SEATTLE, April 24, 2023 /PRNewswire/ -- Avalanche Energy, a fusion energy startup developing modular fusion micro-reactors, today announced that it achieved a record of 200 kilovolts in its micro-fusion reactor and closed a $40M Series A round led by Lowercarbon Capital, with major participation from Founders Fund and Toyota Ventures. Also following on their Seed round investment are Congruent Ventures, Grantham Foundation and Clear Path. New participants also included Autodesk, MCJ Collective and the Climate Capital Syndicate. Avalanche recently operated their second prototype reactor at 200 kilovolts making it the highest known operating voltage of any fusion device since the University of Wisconsin at Madison produced 190 kilovolts in a 2006 experiment. The funding, which follows the company's 2021 $5 million seed round led by Prime Impact Fund, will be used to continue the company's accelerated work to test, develop and optimize its high-voltage orbitron prototypes, in addition to miniaturizing components critical to delivering a stand-alone, micro fusion reactor.

Key Points: 
  • Also following on their Seed round investment are Congruent Ventures, Grantham Foundation and Clear Path.
  • Avalanche Energy has been designing, building and testing micro-fusion reactors that are small enough to fit on a desk since 2021.
  • This new round of funding will allow us to scale up to run more tests at a faster pace that will ultimately enable us to deliver energy producing micro-fusion reactors."
  • In May 2022 , the Defense Innovation Unit awarded a prototype contract to Avalanche Energy to demonstrate the next generation of nuclear propulsion and power generation for spacecraft.

DivInc Launches the Fall 2023 DWeb for Social Impact Accelerator with Support from Filecoin Foundation for the Decentralized Web

Retrieved on: 
Thursday, April 20, 2023
Partnership, Web3, Social impact, Ion District, Decentralized web, Education, Mercury, Ion, Woman, JPMorgan Chase, Organization, Machine learning, Artificial intelligence, Verizon Communications, Growth, Ecosystem, BIPOC, J. P. Morgan, Cryptocurrency

HOUSTON, April 20, 2023 /PRNewswire/ -- DivInc, the premier startup accelerator for people of color and women entrepreneurs, is proud to announce the launch of its Fall 2023 DWeb for Social Impact Accelerator made possible through the support of Filecoin Foundation for the Decentralized Web (FFDW).

Key Points: 
  • HOUSTON, April 20, 2023 /PRNewswire/ -- DivInc, the premier startup accelerator for people of color and women entrepreneurs, is proud to announce the launch of its Fall 2023 DWeb for Social Impact Accelerator made possible through the support of Filecoin Foundation for the Decentralized Web (FFDW).
  • The program also serves as a platform to amplify underrepresented voices in social impact and decentralized web.
  • "A core part of FFDW's mission is education about the decentralized web," said Marta Belcher, president and chair of Filecoin Foundation for the Decentralized Web.
  • The Fall 2023 DWeb for Social Impact Accelerator supported by FFDW is also supported by Houston Premier Partners, J.P. Morgan Chase & Co., Verizon, The Ion, and Mercury.

Intuitive Announces First Quarter Earnings

Retrieved on: 
Tuesday, April 18, 2023
Ion, COVID-19, PDT, GAAP, Public expenditure, Collection, Investment, Da Vinci Surgical System, Growth, Intuitive Surgical, Intuition, Nasdaq, Inc., Geography, Video game

The compound annual growth rate between the first quarter of 2019 and the first quarter of 2023 was approximately 18%.

Key Points: 
  • The compound annual growth rate between the first quarter of 2019 and the first quarter of 2023 was approximately 18%.
  • First quarter 2023 revenue of $1.70 billion increased 14% compared with $1.49 billion in the first quarter of 2022.
  • First quarter 2023 GAAP net income attributable to Intuitive was $355 million, or $1.00 per diluted share, compared with $366 million, or $1.00 per diluted share, in the first quarter of 2022.
  • First quarter 2023 non-GAAP* net income attributable to Intuitive was $437 million, or $1.23 per diluted share, compared with $413 million, or $1.13 per diluted share, in the first quarter of 2022.

Advent Technologies hosts Grand Opening of its State-of-the-Art Fuel Cell R&D and Manufacturing Facility in Boston

Retrieved on: 
Tuesday, April 4, 2023
Hardware, Alternative Energy, State, Local, Green Technology, Energy, Sustainability, Manufacturing, Technology, Batteries, Environmental Policy, Environment, Public Policy, Government, Environmental Health, Other Manufacturing, Other Energy, Engineering, Hydrogen, U.S. Department of Defense Strategy for Operating in Cyberspace, Ion, ADN, Los Alamos National Laboratory, Climate change mitigation, Multimedia, MEA, Electrochemistry, Development, Gross regional domestic product, Electrode, 101 Clarendon Street, New York State Energy Research and Development Authority, MA, Quality control, Growth, Community development, Renewable energy, Advent

View the full release here: https://www.businesswire.com/news/home/20230404005751/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230404005751/en/
    Massachusetts Governor Maura Healey with Advent Technologies Chairman and CEO Dr. Vasilis Gregoriou at the grand opening of the Company’s new facilities at Hood Park in Charlestown, (Boston), MA.
  • Guests toured Advent's new facility, which has:
    State-of-the-art coating machines that support the seamless transition from prototypes to initial production runs for advanced membranes and electrodes of fuel cells.
  • Fuel cell and electrolyzer test stations for statistical process control and development of next-generation membrane electrode assembly (“MEA”) materials.
  • Advent’s newly established facility is expected to create employment opportunities for fuel cell engineers and material scientists in Massachusetts and further contribute to the growth of the clean energy sector.